Drugs / TRASTUZUMAB BOTIDOTIN
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05311397 | Aug 2018 → Jun 2026 overdue | female breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03602079 | Jul 2018 → Jan 2022 | Gaucher ichthyosis restrictive dermopathy, HER2 positive breast carcinoma, breast mucinous carcinoma, cervical cancer +18 | Klus Pharma Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07299825 | Sep 2024 → Sep 2027 expected | HER2 positive breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05346328 | Jun 2022 → Dec 2023 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06968585 | Jul 2023 → Nov 2026 expected | HER2 positive breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRASTUZUMAB BOTIDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314782 ↗ |
| Known as | A166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06968585 ↗ |
| Known as | Trastuzumab botidotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314782 ↗ |
| Known as | Trastuzumab botidotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314782 ↗ |
| Route | Intravenous | “Patients will receive study drug as a single IV infusion.” NCT03602079 ↗ |
| Target | ERBB2 | “Receptor tyrosine-protein kinase erbB-2 binding agent” CHEMBL5314782 ↗ |